Anagrelide
Back to search| Scientific Name: | Anagrelide |
| Brand Name: | Agrylin, Xagrid |
| Company Owner: | Shire development inc, Alphapharm pty ltd, Barr laboratories inc, Impax laboratories inc, Ivax pharmaceuticals inc sub teva pharmaceuticals usa, Mylan laboratories inc, Roxane laboratories inc, Sandoz inc, Watson laboratories |
| Mechanism Of Action | The exact mechanism by which anagrelide lowers platelet count is unclear. Evidence from human trials suggests a dose-related suppression of megakaryocyte maturation, the cells responsible for platelet production – blood drawn from patients receiving anagrelide showed a disruption to the post-mitotic phase of megakaryocyte development and a subsequent reduction in their size and ploidy. |
| Description of the Drug: | Anagrelide is a platelet-reducing agent used to treat thrombocythemia, and its related complications, secondary to myeloproliferative neoplasms. |
| Protein Data Bank: |
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB00261
